Physician profile
Jerry Martel
NPI 1477755668
$510,686.29
in general payments reported to CMS, 2019-2025
40 companies · $138K in 2025
The $138K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $7,215 · 2021: $35K · 2022: $53K · 2023: $70K · 2024: $161K · 2025: $138K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $247K · Travel and Lodging: $43K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $38K · Food and Beverage: $17K · Consulting Fee: $16K · Honoraria: $7,200 · Education: $63.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $246,562.16 |
| Travel and Lodging | $43,105.72 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $37,750.00 |
| Food and Beverage | $17,100.63 |
| Consulting Fee | $16,255.00 |
| Honoraria | $7,200.00 |
| Education | $63.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173,133.36 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Genzyme Corporation | $169,868.14 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $76,437.00 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $38,326.53 | 2023-2025 | Voquezna |
| Qol Medical, LLC | $34,101.27 | 2019-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $3,412.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $3,211.64 | 2019-2025 | |
| Janssen Biotech, INC. | $2,277.64 | 2019-2025 | Stelara, Tremfya |
| Ardelyx, INC. | $1,849.11 | 2022-2025 | Ibsrela |
| Abbott Laboratories | $1,364.77 | 2025 | Aveir |
| Pfizer INC. | $1,139.86 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $780.71 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Ironwood Pharmaceuticals, INC | $667.73 | 2019-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $653.66 | 2019-2025 | Ocaliva |
| Celgene Corporation | $565.96 | 2021-2023 | Zeposia |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $432.29 | 2020-2023 | Movantik, Talicia, Aemcolo |
| Gilead Sciences, INC. | $282.20 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $281.25 | 2024-2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $262.43 | 2019-2024 | Rebyota |
| Aimmune Therapeutics, INC. | $247.22 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $233.71 | 2024-2025 | Vegzelma |
| Daiichi Sankyo INC. | $174.86 | 2019-2022 | |
| Braintree Laboratories, INC. | $154.34 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $150.00 | 2022 | |
| Lilly USA, LLC | $116.22 | 2024-2025 | Omvoh |
| Romark Laboratories, Lc | $90.83 | 2020 | |
| Merck Sharp & Dohme LLC | $86.27 | 2020-2023 | Dificid |
| Evoke Pharma, INC. | $77.22 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $55.40 | 2021-2023 | |
| Amgen INC. | $39.09 | 2022-2023 | Amjevita |
| Vivus LLC | $38.08 | 2021-2024 | Pancreaze |
| Covidien Lp | $24.64 | 2019 | |
| Ethicon US, LLC | $23.98 | 2019 | |
| Ambu INC. | $23.30 | 2021 | |
| Concordia Pharmaceuticals INC. | $22.10 | 2019 | |
| Endo Pharmaceuticals INC. | $20.00 | 2019 | |
| Organon LLC | $18.88 | 2022 | |
| Medtronic, INC. | $16.52 | 2023 | Gi Genius |
| Novo Nordisk INC | $14.57 | 2025 | Wegovy |
| Pentax of America, INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Martel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.